Dipeptides are either organ-specific or are widely present throughout a variety of tissues. Vesilute is one of the latter dipeptides, being found throughout the body[1]. Vesilute is one of the least studied Khavinson peptides, but has shown some effect on bladder and genitourinary system tissues. Research reports indicate that it Vesilute can improve bladder function, particularly in the elderly, assisting with chronic cystitis, benign prostatic hyperplasia (BPH) and a variety of urinary problems. The peptide has important organotrophic effects in the prostate as well, helping to prevent cell proliferation and prostate enlargement. Research suggests that this effect may be the result of improvements in microcirculation. Vesilute and other cytomedines appear to have beneficial effects on sperm quality and fertility. Research out of Russia indicates an increase in sperm production, health, and viability with administration of cytomedines. There is, additionally, a decrease in the number of abnormal sperm. All of these effects serve to increase fertility[2]. Interestingly, the Glu-Asp peptide, along with twelve other dipeptides, has been shown to be responsible for umami flavor in a variety of settings[3]. Though not directly related to health and wellness, the fact that these peptides produce a desirable flavor suggests that their ingestion may be encouraged via evolutionary taste mechanisms. This could, though by no means has been proven to, indicate that these peptides have an important role in basic biochemical processes. Vesilute and other cytomedines have been shown to be orally active[2].

Amino Acid Sequence: Glu-Asp (ED) Molecular Formula: C₉H₁₄N₂O₇ Molecular Weight: 262.20 g/mol PubChem CID: 99716 CAS Number: 3918-84-1 Synonyms: alpha-glutamylaspartic acid, SCHEMBL1674753, vesilut, ED dipeptide Source: PubChem

Vesilute is thought to have anti-aggregation effects on the muscles of the bladder wall. In muscle, glycogen serves as an important form of energy storage. This multibranched polysaccharide is a short-term energy storage solution and is found primarily in muscle and liver cells. It makes up approximately 2% of muscle mass where it serves as an immediate source of glucose to maintain contraction. Glycogen is broken down by an enzyme called glycogen phosphorylase. At rest, glycogen phosphorylase B is in a tense state due to the presence of ATP and certain enzymes. In its tense form, phosphorylation B is unable to bind with glycogen and therefore cannot break it down[4], [5]. Without the ability to breakdown glycogen into glucose, muscle is unable to maintain contraction and is forced to relax. There are multiple stimuli for aggregation in skeletal muscle including the generation of thermal energy (heat), increases in AMP levels, and increases in calcium ion levels. Vesilute appears to interfere with the process of aggregation at a universal step, thereby preventing glycogen breakdown by any mechanism. This, in turn, induces smooth muscle relaxation. Relaxation of smooth muscle ends the signals calling for more energy and can help to break the cycle that leads to spasm. Because smooth muscle is dependent on calcium signals for maintenance, breaking the spasmodic cycle by reducing calcium levels and dissipating heat can lead to long-term relief from spasm. These effects would be highly prominent in the urinary tract where smooth muscle is abundant.

Vesilute en bloedvaten

The effects of Vesilute, which is considered to be a cytomedine peptide, would also be prominent in the vasculature where smooth muscle reigns supreme. Cytomedines, according to Vladimir Khavinson, are peptide bioregulators that prevent premature aging[6]. In this case, interruption of aggregation would lead to vessel relaxation. This would lead to lower blood pressure, reduced energy expenditure in the heart, and improved nutrient delivery to organs throughout the body. Thus, Vesilute 20mg likely has beneficial effects on blood pressure, the long-term health of the vascular system, and several end organs like the heart, brain, and kidneys. It is thought that the benefits of Vesilute on the prostate are due to its microvascular effects. Improved circulation in the prostate helps to reduce inflammation, improve blood flow, and rid the prostate of toxins. The net effect of improved microvascular circulation in the prostate is a decrease in fibrosis and enlargement of the prostate gland. Research shows that prostate massage has a similar effect.

Vesilute en vruchtbaarheid

Interessant is dat het verminderen van prostatitis door het verhogen van de microvasculaire toevoer naar de klier via cytomedines zoals Vesilute een impact lijkt te hebben op spermatogenese. De sperma -niveaus na de behandeling van prostatitis stijgen maar liefst 29% en vertonen meer dan een toename van 14% in de levensvatbaarheid [7]. Onderzoek toont aan dat mannen die worden behandeld met cytomedines zoals Vesilute een toename van de vruchtbaarheid ervaren zonder ondraaglijke bijwerkingen.

Wateroverzicht

Vesilute is een Khavinson -peptide met onderzoek naar de rol van zijn rol bij het reguleren van de urinewegen en de prostaatklier. Onderzoeksbewijs geeft aan dat vesilute kan helpen om de symptomen te verlichten die verband houden met disfunctie van blaas en urinewegen. Van vesilute en andere cytomedines is aangetoond dat ze de prostaatdisfunctie verminderen en worden gedacht dat ze werken door de microcirculatie in de prostaat te verbeteren en door celproliferatie te verminderen. Het laatste effect kan te wijten zijn aan veranderingen in chromosoomdichtheid en epigenetische factoren, een mechanisme van cellulaire regulatie dat gebruikelijk is bij khavinson -peptiden.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russische en Oekraïense academies van medische wetenschappen; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russische Academie van Wetenschappen; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectoren. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries. Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Vesilute. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

1. E. Heidenreich et al., “A Novel UPLC-MS/MS Method Identifies Organ-Specific Dipeptide Profiles,” Int. J. Mol. Sci., Vol. 22, nee. 18, p. 9979, september 2021, doi: 10.3390/ijms22189979.
2. A. A. Kamalov, E. A. Efremov, S. D. Dorofeev, and S. M. Paniushkin, “[Use of oral vitaprost in the treatment of chronic abacterial prostatitis],” Urol. Mosc. Russ. 1999, Nee. 5, pp. 45–50, oktober 2006.
3. Y. Kong et al., “Comparison of non-volatile umami components in chicken soup and chicken enzymatic hydrolysate,” Food Res. Int., Vol. 102, pp. 559–566, december 2017, doi: 10.1016/j.foodres.2017.09.038.
4. T. B. Eronina et al., “Effect of GroEL on thermal aggregation of glycogen phosphorylase b from rabbit skeletal muscle,” Macromol. Biosci., Vol. 10, nee. 7, pp. 768–774, juli 2010, doi: 10.1002/mabi.200900396.
5. "Glycogeen fosforylase B - een overzicht | ScienceDirect -onderwerpen." https://www.sciencedirect.com/topics/neuroscience/glycogen-fosphorylase-b (geraadpleegd op 26 februari 2022).
6. V. G. Morozov and V. K. Khavinson, “[Prospects of cytomedines application in clinical medicine and gerontology],” Klin. Med. (Mosk.), Vol. 78, nee. 2, pp. 42–45, 2000.
7. B. A. Neymark, A. I. Neymark, A. V. Davydov, I. I. Klepikova, N. A. Nozdrachev, and M. V. Razdorskaya, “[ROLE OF CYTOMEDINES IN THE TREATMENT OF PATIENTS WITH CHRONIC PROSTATITIS ASSOCIATED WITH IMPAIRED SPERMATOGENESIS],” Urol. Mosc. Russ. 1999, Nee. 5, pp. 70, 72–73, oktober 2015

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY. De producten die op deze website worden aangeboden, zijn alleen ingericht voor in-vitro-studies. In-vitro-onderzoeken (Latijn: in glas) worden buiten het lichaam uitgevoerd. Deze producten zijn geen medicijnen of medicijnen en zijn niet goedgekeurd door de FDA om een ​​medische aandoening, kwaal of ziekte te voorkomen, te behandelen of te genezen. Lichamelijke introductie van welke aard dan ook in mensen of dieren is ten strengste wettelijk verboden.